CoChat
Sign Up
Cited by 704Lipoproteins and Cardiovascular HealthGenetic Associations and EpidemiologyNutrition, Genetics, and Disease

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

Open access
Mega, Jessica L, Stitziel, Nathan O, Smith, J Gustav, Chasman, Daniel I, Caulfield, Mark J, Devlin, James J, Nordio, Francesco, Hyde, Craig L, Cannon, Christopher P, Sacks, Frank M, Poulter, Neil R, Sever, Peter S, Ridker, Paul M, Braunwald, Eugene, Melander, Olle, Kathiresan, Sekar, Sabatine, Marc S·2015·The Lancet
DOI 10.1016/s0140-6736(14)61730-xPMC PMC4608367
Open this paper in CoChat — free account

Abstract

Background Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.Methods A community-based cohort study (the Malmo Diet and Cancer Study) and four randomised controlled trials of both primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with statin therapy, comprising a total of 48,421 individuals and 3477 events, were included in these analyses. We studied the association of a genetic risk score based on 27 genetic variants with incident or recurrent coronary heart disease, adjusting for traditional clinical risk factors. We then investigated the relative and absolute risk reductions in coronary heart disease events with statin therapy stratified by genetic risk. We combined data from the different studies using a meta-analysis.Findings When individuals were divided into low (quintile 1), intermediate (quintiles 2-4), and high (quintile 5) genetic risk categories, a significant gradient in risk for incident or recurrent coronary heart disease was shown. Compared with the low genetic risk category, the multivariable-adjusted hazard ratio for coronary heart disease for the intermediate genetic risk category was 1·34 (95% CI 1·22-1·47, p<0·0001) and that for the high genetic risk category was 1·72 (1·55-1·92, p<0·0001). In terms of the benefit of statin therapy in the four randomised trials, we noted a significant gradient (p=0·0277) of increasing relative risk reductions across the low (13%), intermediate (29%), and high (48%) genetic risk categories. Similarly, we noted greater absolute risk reductions in those individuals in higher genetic risk categories (p=0·0101), resulting in a roughly threefold decrease in the number needed to treat to prevent one coronary heart disease event in the primary prevention trials. Specifically, in the primary prevention trials, the number needed to treat to prevent one such event in 10 years was 66 in people at low genetic risk, 42 in those at intermediate genetic risk, and 25 in those at high genetic risk in JUPITER, and 57, 47, and 20, respectively, in ASCOT.Interpretation A genetic risk score identified individuals at increased risk for both incident and recurrent coronary heart disease events. People with the highest burden of genetic risk derived the largest relative and absolute clinical benefit from statin therapy.Funding National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)61730-x

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 46 references

Cited by

Sorted by citations

Items 501–600 of 704

Related

See all

Metadata

Authors
Mega, J. L., Stitziel, N. O., Smith, J. G., Chasman, D. I., Caulfield, M. J., Devlin, J. J., Nordio, F., Hyde, C. L., Cannon, C. P., Sacks, F. M., Poulter, N. R., Sever, P. S., Ridker, P. M., Braunwald, E., Melander, O., Kathiresan, S., & Sabatine, M. S.
Affiliations
  • Brigham and Women's Hospital (US)
  • Washington University in St. Louis (US)
  • Broad Institute (US)
  • Queen Mary University of London (GB)
  • Quest Diagnostics (United States) (US)
  • Pfizer (United States) (US)
  • Imperial College London (GB)
  • Lund University (SE)
Corresponding author
  • Mega, Jessica L
  • Stitziel, Nathan O
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-06
Volume
385
Issue
9984
Pages
2264-2271
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(14)61730-x
PMC
PMC4608367
OpenAlex
W2171705978
Cited by
704
References
46
Citations by year
2026: 40 · 2025: 48 · 2024: 51 · 2023: 69 · 2022: 78 · 2021: 83 · 2020: 78 · 2019: 59 · 2018: 62 · 2017: 53 · 2016: 57 · 2015: 25
FWCI
12.58
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
Funders
  • National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) (RC1 HL099634)
  • NIH and the NHLBI (grant K08 HL114642)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
Keywords
coronary artery disease, polygenic risk score, genetic variants, statin therapy, primary prevention, secondary prevention, number needed to treat, risk stratification, JUPITER trial, ASCOT trial, CARE trial, PROVE IT-TIMI 22, recurrent cardiovascular events, Malmö Diet and Cancer Study, cardiovascular risk prediction, treatment benefit stratification, LDL cholesterol lowering
MeSH terms
Coronary Disease, Humans, Primary Prevention, Recurrence, Treatment Outcome, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Secondary Prevention, Numbers Needed To Treat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review